1rui: Difference between revisions

Revision as of 13:00, 29 July 2008

This article has been automatically seeded. Changes to this page should pertain to the PDB entry only and not to the protein or biomolecule in general.

File:1rui.png

Template:STRUCTURE 1rui

RHINOVIRUS 14 MUTANT S1223G COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084RHINOVIRUS 14 MUTANT S1223G COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084

Template:ABSTRACT PUBMED 7473717

About this StructureAbout this Structure

1RUI is a Protein complex structure of sequences from Human rhinovirus 14. Full crystallographic information is available from OCA.

ReferenceReference

Structural studies on human rhinovirus 14 drug-resistant compensation mutants., Hadfield AT, Oliveira MA, Kim KH, Minor I, Kremer MJ, Heinz BA, Shepard D, Pevear DC, Rueckert RR, Rossmann MG, J Mol Biol. 1995 Oct 13;253(1):61-73. PMID:7473717

Page seeded by OCA on Tue Jul 29 13:00:25 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-[[Image:1rui.jpg|left|200px]]
+{{Seed}}
+[[Image:1rui.png|left|200px]]
 <!--
@@ Line 9: / Line 10: @@
 {{STRUCTURE_1rui|  PDB=1rui  |  SCENE=  }}
-'''RHINOVIRUS 14 MUTANT S1223G COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084'''
+===RHINOVIRUS 14 MUTANT S1223G COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084===
-==Overview==
+<!--
-Structures have been determined of three human rhinovirus 14 (HRV14) compensation mutants that have resistance to the antiviral capsid binding compounds WIN 52035 and WIN 52084. In addition, the structure of HRV14 is reported, with a site-directed mutation at residue 1219 in VP1. A spontaneous mutation occurs at the same site in one of the compensation mutants. Some of the mutations are on the viral surface in the canyon and some lie within the hydrophobic binding pocket in VP1 below the ICAM footprint. Those mutant virus strains with mutations on the surface bind better to cells than does wild-type virus. The antiviral compounds bind to the mutant viruses in a manner similar to their binding to wild-type virus. The receptor and WIN compound binding sites overlap, causing competition between receptor attachment and antiviral compound binding. The compensation mutants probably function by shifting the equilibrium in favor of receptor binding. The mutations in the canyon increase the affinity of the virus for the receptor, while the mutations in the pocket probably decrease the affinity of the WIN compounds for the virus by reducing favorable hydrophobic contacts and constricting the pore through which the antiviral compounds are thought to enter the pocket. This is in contrast to the resistant exclusion mutants that block compounds from binding by increasing the bulk of residues within the hydrophobic pocket in VP1.
+The line below this paragraph, {{ABSTRACT_PUBMED_7473717}}, adds the Publication Abstract to the page
+(as it appears on PubMed at http://www.pubmed.gov), where 7473717 is the PubMed ID number.
+-->
+{{ABSTRACT_PUBMED_7473717}}
 ==About this Structure==
@@ Line 34: / Line 38: @@
 [[Category: Icosahedral virus]]
 [[Category: Rhinovirus coat protein]]
-''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May  3 07:55:35 2008''
+''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 13:00:25 2008''